Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Inhibition of SGLT2 reduces blood pressure in the early phase of salt-sensitive hypertension in male Dahl-SS rats independently of changes in renal inflammation.

Created on 03 Jul 2026

Authors

Rawan N Almutlaq, Yotesawee Srisomboon, Sridhatri Guntipally, Andrew N Hakeem, Amanda C Veiga, Jaryd Ross, Babatunde S Anidu, Alex Dayton, Scott M O'Grady, Louise C Evans

Published in

Physiological reports. Volume 14. Issue 13. Pages e70998.

Abstract

Salt-sensitive hypertension is a progressive condition characterized by albuminuria, renal injury, and inflammation. The initiating mechanisms remain unclear. We hypothesized that early in salt-sensitive hypertension, the proximal tubule is exposed to excess albumin, thereby triggering cytokine release and renal inflammation. Blood pressure, renal injury, and inflammation were assessed in Dahl salt-sensitive (SS) rats fed a 4.0% NaCl high-salt (HS) diet for 7 days. Using a proximal tubule cell line, we tested whether albumin exposure triggers epithelial cytokine release, and if this is reduced by dapagliflozin. Lastly, we examined whether dapagliflozin modified the response to 7 days HS in SS rats. Urinary albumin and CCL2 were higher in SS rats fed HS than those fed control salt, prior to differences in blood pressure between the groups. After 7 days, renal macrophage accumulation was higher in HS fed SS rats and correlated positively with albuminuria. Albumin induced CCL2 release from cultured proximal tubule cells; this was prevented by dapagliflozin cotreatment. In SS rats, dapagliflozin blunted the development of salt-induced hypertension but didn't reduce renal macrophage accumulation. Albuminuria is a primary event in SS hypertension and is correlated with renal macrophage accumulation. Inhibition of SGLT2 lowers blood pressure but does not reduce renal inflammation.

PMID:
42397179
Bibliographic data and abstract were imported from PubMed on 03 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement